Stocks Health care VRTX
NASDAQ · Health careVertex Pharmaceuticals Inc / MA (VRTX)
Vertex Pharmaceuticals Inc / MA brought in $12.6B of revenue over the twelve months to June 30, 2026, up 10.2% from a year earlier. Net income was $4.4B, a net margin of 35.0%. Operating cash flow minus capital spending left $3.2B of free cash flow in fiscal 2025. At June 30, 2026 it held $6.1B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Vertex Pharmaceuticals Inc / MA
- Net worth
- Vertex Pharmaceuticals Inc / MA has a market value (market cap) of $129.6B at the latest share price, and shareholders' equity of $20.2B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $12B (+8.9% year on year), with net income of $4B. Over the 12 months to June 30, 2026: revenue $12.6B, net income $4.4B.
- Cash flow
- In fiscal 2025 operations brought in $3.6B of cash; after $437.6M of capital spending, free cash flow was $3.2B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Vertex Pharmaceuticals Inc / MA's next report is expected around November 2, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Vertex Pharmaceuticals Inc / MA does
Vertex Pharmaceuticals develops and commercializes small molecule drugs and gene therapies. The company is best known for developing cystic fibrosis treatments, including Trikafta and Kalydeco. Its therapies are prescribed to patients and sold through specialty pharmacies and distributors. Its shares trade on NASDAQ under the ticker VRTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $12B | $4B | $15.32 | $3.2B |
| 2024 | $11B | -$535.6M | -$2.08 | -$790.3M |
| 2023 | $9.9B | $3.6B | $13.89 | $3.3B |
| 2022 | $8.9B | $3.3B | $12.82 | $3.9B |
| 2021 | $7.6B | $2.3B | $9.01 | $2.4B |
| 2020 | $6.2B | $2.7B | $10.29 | $3B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VRTX ranks in Health care
Latest SEC filings
What Vertex Pharmaceuticals Inc / MA has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 12% to $3.3B versus the same quarter last year; diluted EPS $4.31 versus $3.99.
- August 3, 2026
- July 7, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026Form S-8 POS filing S-8 POS
- May 13, 2026Form S-8 POS filing S-8 POS
- May 13, 2026Form S-8 POS filing S-8 POS
- May 13, 2026Form S-8 POS filing S-8 POS
What is VRTX worth? A DCF from its reported cash flow
Insider trades
What the people running Vertex Pharmaceuticals Inc / MA did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 8, 2026 | van Grunsven JasperEVP, CP and NPPO | Received as pay | 8,682 | - |
| August 28, 2026 | Ambrose KristenSVP & Chief Accounting Officer | Received as pay | 5,000 | - |
| August 27, 2026 | Sachs Bruce IDirector | Gave as a gift | 6,000 | - |
| July 21, 2026 | Sachdev AmitEVP Chief Patient & Ext Af Off | Received as pay | 8,251 | - |
| July 21, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Received as pay | 8,251 | - |
| July 2, 2026 | McKechnie DuncanEVP, Chief Commercial Officer | Soldpre-planned (10b5-1) | 1,541 | $799.8K |
| July 2, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Soldpre-planned (10b5-1) | 1,500 | $787.5K |
| July 1, 2026 | Liu JoyEVP and Chief Legal Officer | Soldpre-planned (10b5-1) | 828 | $416.2K |
Who owns VRTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Capital World Investors13G, passive | 10.1% | May 14, 2026 |
| Capital Research Global Investors13G, passive | 8.3% | May 14, 2026 |
| Vanguard Capital Management13G, passive | 7.49% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,754 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Capital World Investors | 26,115,014 | +746,890 |
| BlackRock, Inc. | 24,109,373 | +139,856 |
| Capital Research Global Investors | 19,490,637 | -1,635,327 |
| Vanguard Capital Management LLC | 16,580,713 | +67,903 |
| State Street Corp | 11,871,459 | +141,320 |
| Invesco Ltd. | 8,043,052 | +150,441 |
| Jpmorgan Chase & Co | 6,517,600 | -515,556 |
| Geode Capital Management, LLC | 6,017,848 | -121,773 |
| Vanguard Portfolio Management LLC | 4,878,987 | -266,622 |
| Capital International Investors | 4,695,144 | -430,933 |
| Loomis Sayles & Co L P | 3,920,953 | -82,868 |
| Franklin Resources Inc | 3,347,253 | +2,796,121 |
| Wellington Management Group Llp | 3,247,658 | +35,069 |
| Morgan Stanley | 3,242,139 | +53,258 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3,086,683 | +29,287 |
| Bank of America Corp | 3,039,178 | +160,995 |
| Jennison Associates LLC | 2,998,530 | +258,471 |
| Norges Bank | 2,971,681 | new |
| Alliancebernstein L.P. | 3,019,315 | -891,471 |
| Ameriprise Financial Inc | 2,604,822 | -28,659 |
Insiders
22 insiders reported holding 504,850 shares in total, about $256M at the last price.
| Holder | Shares |
|---|---|
| Kewalramani ReshmaCEO & President, Director | 98,278 |
| Sachdev AmitEVP Chief Patient & Ext Af Off | 66,512 |
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. | 53,572 |
| Wagner Charles F JrEVP, CO & FO | 47,042 |
| Sachs Bruce IDirector | 39,000 |
| Leiden Jeffrey MExecutive Chairman, Director | 34,797 |
| Altshuler DavidEVP, Chief Scientific Officer | 34,477 |
| Liu JoyEVP and Chief Legal Officer | 19,131 |
| Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. | 18,432 |
| Bozic CarmenEVP and CMO | 15,337 |
Questions about VRTX
What does Vertex Pharmaceuticals Inc / MA do?
Vertex Pharmaceuticals develops and commercializes small molecule drugs and gene therapies. The company is best known for developing cystic fibrosis treatments, including Trikafta and Kalydeco. Its therapies are prescribed to patients and sold through specialty pharmacies and distributors. Its shares trade on NASDAQ under the ticker VRTX.
What is Vertex Pharmaceuticals Inc / MA's net worth?
Vertex Pharmaceuticals Inc / MA has a market value (market cap) of $129.6B at the latest share price, and shareholders' equity of $20.2B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Vertex Pharmaceuticals Inc / MA profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $4.4B on revenue of $12.6B, a net margin of 35.0%.
How much revenue does Vertex Pharmaceuticals Inc / MA make?
Over the twelve months to June 30, 2026 Vertex Pharmaceuticals Inc / MA reported revenue of $12.6B. That is 10.2% more than a year earlier.
When did Vertex Pharmaceuticals Inc / MA last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
When is Vertex Pharmaceuticals Inc / MA's next earnings report?
Vertex Pharmaceuticals Inc / MA's next report is expected around November 2, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VRTX with
Follow VRTX
Get an email when Vertex Pharmaceuticals Inc / MA files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vertex Pharmaceuticals Inc / MA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.